Search for drugs:
Typing the drug name to query
IOTHALAMATE MEGLUMINE
DIR Classification
Classification:Most-DIR concern
Severity Score:4
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- WARNINGS
- SEVERE ADVERSE EVENTS – INADVERTENT INTRATHECAL ADMINISTRATION: Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to ensure that this drug product is not administered intrathecally.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
Rhabdomyolysis
7
42905
Other ADRs
335
14116944
Odds Ratio = 6.876
Drug Property Information
ATC Code(s):
- V08AA04 - iothalamate meglumine
- V08AA - "Watersoluble, nephrotropic, high osmolar X-ray contrast media"
- V08A - "X-RAY CONTRAST MEDIA, IODINATED"
- V08 - CONTRAST MEDIA
- V - VARIOUS
Active Ingredient:iothalamate meglumine
Active Ingredient UNII:XUW72GOP7W
Drugbank ID:DB09133
PubChem Compound:3737
CAS Number:2276-90-6
Dosage Form(s):injection
Route(s) Of Administrator:ureteral
Daily Dose:
Chemical Structure: 
SMILE Code:
CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I
CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I
Reference
COHORT STUDY:
N/AOTHER REFERENCE(S):
N/ADisclaimer:
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.